Natera (NASDAQ:NTRA) Reaches New 12-Month High – Should You Buy?

15 Sep 2026, 11:01 by Doug Wharley · The Cerbat Gem

Natera, Inc. (NASDAQ:NTRA – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $347.10 and last traded at $345.3630, with a volume of 67550 shares changing hands. The stock had previously closed at $341.79.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several research analyst reports. Piper Sandler upped their price target on shares of Natera from $249.00 to $363.50 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Rothschild & Co Redburn started coverage on shares of Natera in a research note on Tuesday, September 8th. They set a “buy” rating and a $385.00 price objective for the company. BTIG Research upped their price objective on Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a report on Friday, August 7th. The Goldman Sachs Group started coverage on Natera in a research report on Friday, June 5th. They issued a “neutral” rating and a $245.00 target price on the stock. Finally, Royal Bank Of Canada upgraded Natera from an “outperform” rating to a “buy” rating in a report on Tuesday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $330.83.

Get Our Latest Stock Analysis on Natera

Natera Price Performance

The firm has a 50-day simple moving average of $298.96 and a 200 day simple moving average of $242.82. The company has a market capitalization of $49.21 billion, a PE ratio of -250.14 and a beta of 1.54.

Natera (NASDAQ:NTRA – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.02. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%.The company had revenue of $752.75 million during the quarter, compared to the consensus estimate of $661.24 million. During the same quarter in the prior year, the business earned ($0.74) earnings per share. The company’s revenue was up 37.7% compared to the same quarter last year. Equities research analysts expect that Natera, Inc. will post -1.02 EPS for the current fiscal year.

Insider Activity

In other Natera news, insider John Fesko sold 6,517 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $321.53, for a total value of $2,095,411.01. Following the completion of the transaction, the insider owned 197,257 shares in the company, valued at $63,424,043.21. This represents a 3.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 2,419 shares of the stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $253.96, for a total transaction of $614,329.24. Following the completion of the sale, the chief financial officer directly owned 54,295 shares of the company’s stock, valued at $13,788,758.20. This trade represents a 4.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 68,242 shares of company stock worth $19,301,534 in the last ninety days. 5.05% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently added to or reduced their stakes in NTRA. Trust Co. of Vermont purchased a new stake in shares of Natera during the second quarter worth about $26,000. Reflection Asset Management acquired a new stake in Natera during the 4th quarter valued at approximately $29,000. Elevation Wealth Partners LLC purchased a new stake in Natera during the 2nd quarter worth approximately $30,000. Palladiem LLC acquired a new position in shares of Natera in the 4th quarter valued at approximately $31,000. Finally, Continuum Advisory LLC acquired a new position in shares of Natera in the 2nd quarter valued at approximately $33,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

About Natera

(Get Free Report)

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services based on cell-free DNA and other genomic technologies. The company focuses on reproductive health, oncology and organ health, providing tests intended to support screening, diagnosis, treatment planning and disease monitoring.